Minerva Neurosciences, based in Cambridge, MA, is a clinical-stage biopharmaceutical company specializing in central nervous system disorders. With a focus on patient benefit, they design innovative trials and develop product candidates for conditions such as schizophrenia and Parkinson's disease.
Driven by clinical expertise and a commitment to patient care, Minerva Neurosciences aims to advance treatments that address unmet medical needs in the field of neurology. Their innovative pipeline includes promising candidates like Roluperidone, MIN-101, and MIN-301, reflecting their dedication to improving the lives of those affected by neurological conditions.
Generated from the website